These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22207981)

  • 1. [Usefulness of PSA isoform].
    Okegawa T
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():254-8. PubMed ID: 22207981
    [No Abstract]   [Full Text] [Related]  

  • 2. [Usefulness of PSA isoform and related parameter].
    Okegawa T
    Nihon Rinsho; 2016 May; 74 Suppl 3():300-4. PubMed ID: 27344746
    [No Abstract]   [Full Text] [Related]  

  • 3. Precursor isoform of prostate-specific antigen and human kallikrein 2: two new promising biomarkers for the unsolved challenge of early prostate cancer detection.
    Ficarra V; Novara G; Galfano A
    Eur Urol; 2009 Mar; 55(3):556-9. PubMed ID: 19111385
    [No Abstract]   [Full Text] [Related]  

  • 4. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p2PSA but not total and free PSA increases after myocardial infarction: results of a preliminary investigation.
    Lippi G; Aloe R; Cervellin G
    Int J Cardiol; 2011 Nov; 153(1):119. PubMed ID: 21968074
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urol Oncol; 2005; 23(1):16-21. PubMed ID: 15885578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N; Ohyama C; Habuchi T
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
    Stephan C; Schnorr D; Loening SA; Jung K
    Eur Urol; 2005 Dec; 48(6):1059-60; author reply 1060-1. PubMed ID: 16260082
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
    Abrahamsson PA; Kuriyama M
    Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.
    Jansen FH; van Schaik RH; Kurstjens J; Horninger W; Klocker H; Bektic J; Wildhagen MF; Roobol MJ; Bangma CH; Bartsch G
    Eur Urol; 2010 Jun; 57(6):921-7. PubMed ID: 20189711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.
    Roddam AW; Hamdy FC; Allen NE; Price CP;
    BJU Int; 2007 Sep; 100(3):514-7. PubMed ID: 17542987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial comment. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
    Bartoletti R; Cai T
    Urology; 2011 Mar; 77(3):e1; author reply e2. PubMed ID: 21376994
    [No Abstract]   [Full Text] [Related]  

  • 15. Screening for prostatic carcinoma with prostate specific antigen.
    Waidelich R; Jansen HM; Stieber P; Schmeller N; Lamerz R; Werdan K; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):2979-81. PubMed ID: 9329580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The usefulness of prostate-specific antigen assay for the early detection and follow up of the prostate cancer].
    Saito Y
    Nihon Rinsho; 1998 Aug; 56(8):1989-93. PubMed ID: 9750493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity and legacy of prostate-specific antigen (PSA) and PSA-based parameters and isoforms in the new millennium.
    Djavan B
    Eur Urol; 2010 Jun; 57(6):928-9. PubMed ID: 20304552
    [No Abstract]   [Full Text] [Related]  

  • 18. [Usefulness of PSA test for diagnosis of prostatic cancer].
    Yamanaka Y; Takahashi S
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():233-7. PubMed ID: 22207978
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF; Mensink HJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What to do with an abnormal PSA test.
    Loeb S; Catalona WJ
    Oncologist; 2008 Mar; 13(3):299-305. PubMed ID: 18378540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.